Cognitive Dysfunction And Bumetanide Treatment In A Valproate-Induced Rat Model Of Autism
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE(2016)
摘要
Cognitive dysfunction is an important aspect of the clinical characteristics of autism; however, research has often focused on social cognition. Learning and memory disorders often occur in autistic children, which are particularly under examined. Using cognitive and behavioral measures in our study, these disorders were endorsed in a valproate-induced rat model of autism. We identified increased levels of serum 5-hydroxytryptamine (5-HT) and gamma-aminobutyric acid (GABA), clear neuropathological changes, and enhanced protein expression levels of the N-methyl-D-aspartate (NMDA) receptor subunits NR2A and NR2B (NR2A, NR2B) and calcium/calmodulin-dependent protein kinase II (CaMK II), which suggests that these changes may have a role in the cognitive dysfunction of autism. Bumetanide has increasingly been used for the experimental treatment of autism. Thus, we treated model rats with Bumetanide and identified improvements in cognitive and behavioral measures. The current findings suggest that bumetanide may have potential long-term effects in the treatment of autism. Moreover, the effects of this drug may have a functional role through inhibition of the NKCC1 transporter.
更多查看译文
关键词
Autism, cognitive dysfunction, valproic acid, bumetanide
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要